ストックスクリーナーアプリを入手
7.0226
67.60%
2.8326
Bolt Biotherapeutics Inc (BOLT) 最新ニュース
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock By Investing.com - Investing.com South Africa
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock - Investing.com India
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock - Investing.com
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares By Investing.com - Investing.com India
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares By Investing.com - Investing.com Canada
Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares - Investing.com
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares - Investing.com
Bolt Biotherapeutics (BOLT) CEO logs stock sales and an ESPP buy - Stock Titan
Bolt Biotherapeutics (BOLT) Climbs 6.43% to $3.56 as Shares Test Upper RangeMcClellan Oscillator - careplusvn.com
BOLT - Finviz
BOLT Q2 2026 Earnings: Wider-than-Expected Per-Share Loss of -$4.57 Highlights Cost PressuresEBITDA Margin Trends - vinanet.vn
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Barchart.com
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Return On Assets - vinanet.vn
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Earnings Deceleration Risk - careplusvn.com
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Balance Sheet Strength - dars.gov.et
Bolt Biotherapeutics (BOLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bolt (BOLT) Levels: Records a 2.60% Increase to $3.26 in the Current Update; Price Context: the Near-Term Reference Band Stretches From $3.10 to $3.42 in the Current UpdateTrend Following Picks - vinanet.vn
Bolt (BOLT) Quarterly Figures: The EPS Result Is Below Expectation; Price Reaction: Shares Fall 0.72%Buyback Announcement Report - vinanet.vn
Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - Vinanet
Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - vinanet.vn
Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics - Stock Titan
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BOLT Looks 49.0% Undervalued on GF Value™ Despite Clinical-Stage Challenges - GuruFocus
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot - KHOU
Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity - TradingView
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary - TradingView
BOLT: BDC-4182 trial progresses as cash runway extends into Q1 2027 amid lower Q2 expenses - TradingView
Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M - Stock Titan
Press Release: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - primepublishers.com
Bolt Biotherapeutics' Cancer Trial Data Expected With Q3 Results - Stock Titan
Bolt Biotherapeutics (BOLT) Advances 4.65% as Buyers Defend Key SupportHigh Volume Node - vinanet.vn
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BOLT Q2'26 Earnings: revenue estimate is 500.00K USD - TradingView
BOLT|Bolt Biotherapeutics Inc|Price:3.580|Chg%:-0.010 - TradingKey
Bolt Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Bolt Biotherapeutics Inc (BOLT) Cash Flow - TradingKey
TradingKey - TradingKey
BOLT|Bolt Biotherapeutics Inc|Price:3.830|Chg%:+0.110 - TradingKey
BOLT Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerAdjusted Earnings Analysis - careplusvn.com
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BOLT Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerEarnings Season Review - dars.gov.et
Curis (CRIS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $CRIS - MarketBeat
7.17%
0.00%
大文字化:
|
ボリューム (24 時間):